Improving Outcomes in Patients with Atrial Fibrillation: An Update for the Primary Care Provider

Des Moines, IA US
April 20, 2013

Atrial fibrillation (AFib) is the most common heart rhythm disorder seen by primary care physicians. AFib affects an estimated 2.7 million people in the United States and the incidence is expected to double within the next forty years. AFib negatively impacts patient’s quality of life and is a major risk factor for stroke. Despite practice guidelines for managing AFib, it’s estimated that two-thirds of AFib-related strokes can be avoided. Gaps exist between the evidence base and clinical practice. Stroke in patients with AFib result in worse outcomes including higher mortality, greater functional impairment and dependency. Although existing guidelines define effective therapeutic strategies for managing AFib to reduce stroke risk, these strategies are frequently underused or inappropriately understood. Both provider and patient knowledge and attitudes play an important role in the success of current strategies to manage AFib to prevent stroke.

Course Directors

  • Kevin Carnevale, MD
    Academic Pathologist, Microbiology and Immunology, Des Moines University
     
  • Craig B. Clark, DO, FACC, FAHA, FASE
    Cardiologist, Iowa Health Cardiology; Immediate Past-President, Iowa Chapter of the American College of Cardiology

Target Audience

Primary care physicians, internists, hospitalists, cardiologists, neurologists, anticoagulation and thrombosis specialists, residents, physician assistants, nurses, nurse practitioners, cardiac techs, support staff, and all other interested health professionals.

Objectives

  • Describe the incidence and consequences of untreated atrial fibrillation.
  • Identify patients for whom antithrombotic management for atrial fibrillation or atrial flutter is appropriate.
  • Document the risk of stroke using a validated assessment tool.
  • Determine the relative risk and benefit of antithrombotic therapy for a given patient.
  • Select the appropriate antithrombotic therapy including the role of newly approved antithrombotic agents.
  • Determine which patients are best managed with a rate-control versus rhythm-control strategy.
  • Discuss options for maintaining sinus rhythm including anti-arrhythmic drug therapy and the role of ablation.
  • Recite emerging therapies for atrial fibrillation and prevention of its complications.

Agenda

Download presentation objectives.

7:30 amRegistration and Breakfast
8 am 

Epidemiology, Natural History and Risk Factors for Atrial Fibrillation

Gary Hoff, DO, FACOI, FACC, Des Moines University

Dr. Hoff indicated he has no financial relationships to disclose relevant to the content of this CME activity.

8:20 am

Recent Insights into the Mechanisms of Atrial Fibrillation

Samuel J. Asirvatham, MD, Cardiology and Vascular Medicine, Mayo Clinic, MN

Dr. Asirvatham indicated he has received an honoraria for consulting with Abiomed, Biotronik, Boston Scientific, Medtronic, Spectranetics, St. Jude, Sanofi‐Aventis, Stereotaxis, Wolters Kluwer, and Elsevier. He is also copatent holder and may receive future royalties from Nevro, Aegis, and ATP.

8:50 am

Working Up the Patient with Newly Diagnosed Atrial Fibrillation

Lisa Benton, NP, CCA, State Representative

Ms. Benton indicated she has no financial relationships to disclose relevant to the content of this CME activity.

9:10 am

Assessing Stroke Risk: Who Needs to be Anticoagulated?

Calvin J. Hansen, MD, Iowa Health Des Moines

Dr. Hansen indicated he has no financial relationships to disclose relevant to the content of this CME activity.

9:30 amBreak
10 am 

Which Drug for Which Patient? Coumadin or the Newer Agents: Current Status and Review

Samuel J. Asirvatham, MD

10:40 am 

Trips, Falls, and Spills: The Geriatrician’s Perspective on Anticoagulating

Darrel E. Devick, DO, FACOI, Mercy Capitol Internal Medicine Clinic

Dr. Devick indicated he has no financial relationships to disclose relevant to the content of this CME activity.

11 amPanel Discussion and Case Presentations
11:30 am

Rate Versus Rhythm Control AFFIRMING the Right Choice

Craig B. Clark, DO, FACC, FAHA, FASE, Iowa Health Cardiology; Iowa Chapter of the American College of Cardiology

Dr. Clark indicated he has no financial relationships to disclose relevant to the content of this CME activity.

12 pmLunch
1 pm

Antiarrhythmic Drug Therapy in Atrial Fibrillation

Prasad R. Palakurthy, MD, FACC, FHRS,Electrophysiologist, Iowa Health Cardiology

Dr. Palakurthy indicated he has no financial relationships to disclose relevant to the content of this CME activity.

1:30 pm

Ablative Therapy for Atrial Fibrillation

Robert H. Hoyt, MD, FACC, FHRS, Electrophysiologist, Iowa Heart Center

Relevant to this CME activity, Dr. Hoyt indicated he has received an honorarium from Medtronic and Boehringer Ingelheim.

2 pm

What the Provider Needs to Know When Their Patient Returns to the Office After an Ablation

Christopher J. Mcleod, MBChB, PhD, Cardiology and Vascular Medicine, Mayo Clinic, MN

Dr. McLeod indicated he has no financial relationships to disclose relevant to the content of this CME activity.

2:20 pm

Recent Advances in Treatment of Atrial Fibrillation: Non-Pharmacological Stroke Prevention

Alexander Mazur, MD, University of Iowa Carver College of Medicine

Dr. Mazur indicated he has no financial relationships to disclose relevant to the content of this CME activity.

2:50 pmBreak
3:10 pmInteractive Patient Cases
4:10 pm

Provider and Patient Resources

Kevin Carnevale, MD, Des Moines University

Dr. Carnevale indicated he has no financial relationships to disclose relevant to the content of this CME activity.

4:30 pmAdjourn

Resources

A complete list of the patient/provider resources can be found here.

Registration

Attendees will be requested to complete a short learner self-assessment survey regarding their present and desired level of ability to administer antithrombotic therapy for patients with AFib. The information will be used to enhance the learning experience. The response, rationale, and references to each answer will be supplied at the educational activity. We thank you in advance for your time.

  • Physician – $50
  • Non-Physicians  $25
  • Students and residents – Free

Commercial Support

This activity is funded through an educational grant from Bristol-Myers Squibb/Pfizer Pharmaceuticals Partnership to the TEAM-A Collaborative to support activities that improve the treatment of patients with Atrial Fibrillation.  The Physicians’ Institute is a member of TEAM-A and retains full control over the distribution of individual grants under this collaborative grant program.

Exhibitors

Thank you to St. Jude Medical, Boehringer Ingelheim and Medtronic for their support.

Continuing Education Credit

  • AAMA: 7.0 CEUs, either- Clinical or General.
  • AAFP: This Live activity, Improving Outcomes in Patient with Atrial Fibrillation: An Update for the Primary Care Physician, with a beginning date of 04/20/2013, has been reviewed and is acceptable for up to 6.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • MD: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Iowa Medical Society (IMS) through joint sponsorship of Iowa Health-Des Moines (Methodist & Lutheran/Blank Children’s) and Des Moines University. Iowa Health-Des Moines (Methodist & Lutheran/Blank Children’s) is accredited by the IMS to provide continuing medical education for physicians. Iowa Health-Des Moines (Methodist & Lutheran/Blank Children’s) designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) and approves this live activity for 6.5 Category 1-A CME credit(s).
  • Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 8.0 continuing education contact hour(s). No partial credit awarded.
  • Other: This live activity is designated for 6.75 AMA PRA Category 1 Credit(s)™.
Course summary
Available credit: 
  • 6.50 AOA Category 1­A
  • 6.75 AMA PRA Category 1 Credits
  • 8.00 IBON
  • 6.75 CE Contact Hours
  • 6.75 AAFP
Course opens: 
04/20/2013
Course expires: 
04/20/2013
Event starts: 
04/20/2013 - 8:00am
Event ends: 
04/20/2013 - 4:30pm
Cost:
$50.00
Rating: 
0
Des Moines University
3200 Grand Avenue
Student Education Center Auditorium
Des Moines, IA 50312
United States

Available Credit

  • 6.50 AOA Category 1­A
  • 6.75 AMA PRA Category 1 Credits
  • 8.00 IBON
  • 6.75 CE Contact Hours
  • 6.75 AAFP

Accreditation Period

Course opens: 
04/20/2013
Course expires: 
04/20/2013

Price

Cost:
$50.00
Please login or Create an Account to take this course.